Biofrontera appoints George Jones as Chief Commercial Officer effective August 25, 2025

Biofrontera Inc.

George Jones named CCO of Biofrontera (Nasdaq: BFRI), bringing over 25 years of commercial leadership in pharmaceuticals and biotech.
Compensation: $315,000 base salary, up to 50% bonus, and at least 100,000 stock options with one-year vesting per year over three years.
Jones previously served as COO at UpScriptHealth, where partnership revenues increased more than threefold, and held VP roles at Currax Pharmaceuticals and Pernix Therapeutics.
Appointment follows Biofrontera's agreement to acquire US rights to Ameluz and RhodoLED from Biofrontera AG, reducing royalty from 25%-35% to 12%-15% of net sales.
Company states the management strengthening and improved royalty terms will bring it significantly closer to cash break-even.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.